Influence networks based on coexpression improve drug target discovery for the development of novel cancer therapeutics

BMC Systems Biology

Volumn 8, Issue 1, 2014, Pages

  Penrod, Nadia M ^a   Moore, Jason H ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Breast cancer; Coexpression networks; Drug target discovery; Letrozole; Tumor adaptation

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; LETROZOLE; MESSENGER RNA; NITRILE; TRIAZOLE DERIVATIVE;

ARTICLE; BIOLOGY; BREAST TUMOR; DRUG DEVELOPMENT; GENE EXPRESSION PROFILING; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMPUTATIONAL BIOLOGY; DRUG DISCOVERY; GENE EXPRESSION PROFILING; HUMANS; MOLECULAR TARGETED THERAPY; NITRILES; RECEPTORS, ESTROGEN; RNA, MESSENGER; TRIAZOLES;

EID: 84893196547     PISSN: None     EISSN: 17520509     Source Type: Journal    
DOI: 10.1186/1752-0509-8-12     Document Type: Article

References (34)

1. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol 2007, 25(2):209-216. 10.1200/JCO.2006.09.0803, 17210942.
2. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov 2004, 3(8):711-716. 10.1038/nrd1470, 15286737.
3. Walker I, Newell H. Do molecularly targeted agents in oncology have reduced attrition rates?. Nat Rev Drug Discov 2008, 8:15-16.
4. Barabási A, Oltvai Z. Network biology: understanding the cell's functional organization. Nat Rev Genet 2004, 5:101-113. 10.1038/nrg1272, 14735121.
5. Yu H, et al. The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics. PLoS Comput Biol 2007, 3:0713-0720.
6. Miller W, Larionov A, Renshaw L, Anderson T, White S, Murray J, Murray E, Hampton G, Walker J, Ho S, et al. Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenet Genom 2007, 17(10):813-826.
7. Miller W, Larionov A, Anderson T, Evans D, Dixon J. Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole. Pharmacogenomics J 2012, 12:10-21. 10.1038/tpj.2010.67, 20697427.
8. Dai M, Wang P, Boyd A, Kostov G, Athey B, Jones E, Bunney W, Myers R, Speed T, Akil H, et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 2005, 33(20):e175-e175. 10.1093/nar/gni179, 1283542, 16284200.
9. Irizarry R, Hobbs B, Collin F, Beazer-Barclay Y, Antonellis K, Scherf U, Speed T. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4(2):249-264. 10.1093/biostatistics/4.2.249, 12925520.
10. Smyth G. limma: Linear Models for Microarray Data 2005, 397-420, Springer New York, Smyth, G: limma: Linear Models for Microarray Data. In Bioinformatics and Computational Biology Solutions Using R and Bioconductor. Edited by Gentleman R, Carey VJ, Huber W, Irizarry RA, Dudoit S. New York: Springer; 2005: 397-420.
11. Jeffery I, Higgins D, Culhane A. Comparison and evaluation of methods for generating differentially expressed gene lists from microarray data. BMC Bioinformatics 2006, 7:359. 10.1186/1471-2105-7-359, 1544358, 16872483.
12. de la Fuente A, Bing N, Hoeschele I, Mendes P. Discovery of meaningful associations in genomic data using partial correlation coefficients. Bioinformatics 2004, 20(18):3565-3574. 10.1093/bioinformatics/bth445, 15284096.
13. Csardi G, Nepusz T. The igraph software package for complex network research. InterJournal 2006, Complex Systems:1695. [http://igraph.sf.net].
14. Hangal S, MacLean D, Lam MS, Heer J. All friends are not equal: Using weights in social graphs to improve search. Proceedings of the 4th SNA-KDD Workshop '10 (SNA-KDD'10) 2010, Washington D.C.: ACM.
15. Koh JL, Brown KR, Sayad A, Kasimer D, Ketela T, Moffat J. COLT-Cancer: functional genetic screening resource for essential genes in human cancer cell lines. Nucleic Acids Res 2012, 40(D1):D957-D963. 10.1093/nar/gkr959, 3245009, 22102578.
16. Marcotte R, Brown KR, Suarez F, Sayad A, Karamboulas K, Krzyzanowski PM, Sircoulomb F, Medrano M, Fedyshyn Y, Koh JL, et al. Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov 2012, 2(2):172-189. 10.1158/2159-8290.CD-11-0224, 22585861.
17. Penrod NM, Moore JH. Key genes for modulating information flow play a temporal role as breast tumor coexpression networks are dynamically rewired by letrozole. BMC Med Genomics 2013, 6(Suppl 2):S2.
18. Woo IS, Jin H, Kang ES, Kim HJ, Lee JH, Chang KC, Park JY, Choi WS, Seo HG. TMEM14A inhibits N-(4-hydroxyphenyl) retinamide-induced apoptosis through the stabilization of mitochondrial membrane potential. Cancer Lett 2011, 309(2):190-198. 10.1016/j.canlet.2011.05.031, 21723035.
19. Chea E. Regulation of planar cell polarity and Vangl2 trafficking by Tmem14a. Master's thesis, University of Toronto 2012.
20. Cantrell VA, Jessen JR. The planar cell polarity protein Van Gogh-Like 2 regulates tumor cell migration and matrix metalloproteinase-dependent invasion. Cancer Lett 2010, 287:54-61. 10.1016/j.canlet.2009.05.041, 19577357.
21. Fortes M, Reverter A, Nagaraj S, Zhang Y, Jonsson N, Barris W, Lehnert S, Boe-Hansen G, Hawken R. A single nucleotide polymorphism-derived regulatory gene network underlying puberty in 2 tropical breeds of beef cattle. J Anim Sci 2011, 89:1669-1683. 10.2527/jas.2010-3681, 21357453.
22. Hemmi K, Ma D, Miura Y, Kawaguchi M, Sasahara M, Hashimoto-Tamaoki T, Tamaoki T, Sakata N, Tsuchiya K. A homeodomain-zinc finger protein, ZFHX4, is expressed in neuronal differentiation manner and suppressed in muscle differentiation manner. Biol Pharm Bull 2006, 29:1830-1835. 10.1248/bpb.29.1830, 16946494.
23. de Cabo R, Siendones E, Minor R, Navas P. CYB5R3: a key player in aerobic metabolism and aging?. Aging (Albany NY) 2010, 2:63-68.
24. Sanchez-Alvarez R, Martinez-Outschoorn UE, Lamb R, Hulit J, Howell A, Gandara R, Sartini M, Rubin E, Lisanti MP, Sotgia F. Mitochondrial dysfunction in breast cancer cells prevents tumor growth: Understanding chemoprevention with metformin. Cell Cycle 2013, 12:172-182. 10.4161/cc.23058, 3570509, 23257779.
25. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucl Acids Res 2011, 39(suppl 1):D1035-D1041. 3013709, 21059682.
26. Luscombe NM, Babu MM, Yu H, Snyder M, Teichmann SA, Gerstein M. Genomic analysis of regulatory network dynamics reveals large topological changes. Nature 2004, 431(7006):308-312. 10.1038/nature02782, 15372033.
27. Edwards AM, Isserlin R, Bader GD, Frye SV, Willson TM, Frank HY. Too many roads not taken. Nature 2011, 470(7333):163-165. 10.1038/470163a, 21307913.
28. White JK, Gerdin AK, Karp NA, Ryder E, Buljan M, Bussell JN, Salisbury J, Clare S, Ingham NJ, Podrini C, et al. Genome-wide generation and systematic phenotyping of knockout mice reveals new roles for many genes. Cell 2013, 154(2):452-464. 10.1016/j.cell.2013.06.022, 3717207, 23870131.
29. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674. 10.1016/j.cell.2011.02.013, 21376230.
30. Ashworth A, Lord C, Reis-Filho J. Genetic interactions in cancer progression and treatment. Cell 2011, 145:30-38. 10.1016/j.cell.2011.03.020, 21458666.
31. Krainick-Strobel UE, Lichtenegger W, Wallwiener D, Tulusan AH, Jänicke F, Bastert G, Kiesel L, Wackwitz B, Paepke S. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer 2008, 8:62. 10.1186/1471-2407-8-62, 2270851, 18302747.
32. Llombart-Cussac A, Guerrero T, Galán A, Carañana V, Buch E, Rodríguez-Lescure T, Ruiz A, Fuster Diana C, Guillem Porta V. Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR [+] operable breast cancer. Clin Transl Oncol 2012, 14(2):125-131. 10.1007/s12094-012-0771-9, 22301401.
33. Allevi G, Strina C, Andreis D, Zanoni V, Bazzola L, Bonardi S, Foroni C, Milani M, Cappelletti M, Gussago F, et al. Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. Br J Cancer 2013, 108(8):1587-1592. 10.1038/bjc.2013.151, 23579222.
34. Dixon J, et al. Increase in response rate by prolonged treatment with neoadjuvant letrozole. Breast Cancer Res Treat 2009, 113:145-151. 10.1007/s10549-008-9915-6, 18264759.